|
English
|
正體中文
|
简体中文
|
2817721
|
|
???header.visitor??? :
27846901
???header.onlineuser??? :
345
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"polli a"???jsp.browse.items-by-author.description???
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 中山醫學大學 |
2021 |
Efficacy of Lorlatinib in Treatment-Naive Patients (pts) With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Relation to EML4-ALK Variant Type and ALK Mutations.
|
Bearz, A; Martini, JF; Jassem, J; Kim, SW; Chang, GC; Shaw, A; Shepard, D; Dall'O', E; Polli, A; Thurm, H; Zalcman, G; Campelo, MRG; Penkov, K; Hayashi, H; Solomon, BJ |
| 臺大學術典藏 |
2020-12-02T02:33:14Z |
Final results of the large-scale multinational trial PROFILE 1005: Efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer
|
Blackhall F.; Ross Camidge D.; Shaw A.T.; Soria J.-C.; Solomon B.J.; Mok T.; Hirsh V.; J?Nne P.A.; Shi Y.; Pan-Chyr Yang; De Pas T.; Hida T.; De Castro Carpe?O J.; Lanzalone S.; Polli A.; Iyer S.; Reisman A.; Wilner K.D.; Kim D.-W.; Blackhall F.; PAN-CHYR YANG et al. |
| 國立臺灣大學 |
2012 |
UPDATED RESULTS OF A GLOBAL PHASE II STUDY WITH CRIZOTINIB IN ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
|
Kim, D.; Ahn, M.; Yang, P.; Liu, X.; De Pas, T.; Crino, L.; Lanzalone, S.; Polli, A.; Shaw, A. |
Showing items 1-3 of 3 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
